Arecor Therapeutics Future Growth
Future criteria checks 0/6
Arecor Therapeutics's revenue is forecast to decline at 69% per annum.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs earnings growth | 20.5% |
| Revenue growth rate | -69.0% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 15 Oct 2025 |
Recent future growth updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 1 | N/A | -1 | N/A | 1 |
| 12/31/2026 | 1 | N/A | -4 | N/A | 2 |
| 12/31/2025 | 3 | N/A | -1 | N/A | 2 |
| 6/30/2025 | 5 | -8 | -6 | -6 | N/A |
| 3/31/2025 | 5 | -9 | -8 | -8 | N/A |
| 12/31/2024 | 5 | -10 | -9 | -9 | N/A |
| 9/30/2024 | 5 | -9 | -7 | -7 | N/A |
| 6/30/2024 | 5 | -9 | -6 | -6 | N/A |
| 3/31/2024 | 5 | -9 | -6 | -6 | N/A |
| 12/31/2023 | 5 | -9 | -6 | -6 | N/A |
| 9/30/2023 | 4 | -9 | -9 | -8 | N/A |
| 6/30/2023 | 3 | -9 | -11 | -11 | N/A |
| 3/31/2023 | 3 | -9 | -11 | -11 | N/A |
| 12/31/2022 | 2 | -9 | -11 | -11 | N/A |
| 9/30/2022 | 2 | -8 | -10 | -9 | N/A |
| 6/30/2022 | 1 | -7 | -8 | -8 | N/A |
| 3/31/2022 | 1 | -7 | -7 | -7 | N/A |
| 12/31/2021 | 1 | -6 | -6 | -5 | N/A |
| 9/30/2021 | 1 | -5 | -4 | -4 | N/A |
| 6/30/2021 | 1 | -5 | -3 | -3 | N/A |
| 3/31/2021 | 2 | -4 | -3 | -2 | N/A |
| 12/31/2020 | 2 | -3 | -2 | -2 | N/A |
| 12/31/2019 | 2 | -2 | 0 | 0 | N/A |
| 5/31/2019 | 1 | -2 | N/A | -3 | N/A |
| 5/31/2018 | 1 | -1 | N/A | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if AREC's forecast earnings growth is above the savings rate (3%).
Earnings vs Market: Insufficient data to determine if AREC's earnings are forecast to grow faster than the UK market
High Growth Earnings: Insufficient data to determine if AREC's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: AREC's revenue is expected to decline over the next 3 years (-69% per year).
High Growth Revenue: AREC's revenue is forecast to decline over the next 3 years (-69% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AREC's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/19 14:00 |
| End of Day Share Price | 2025/11/19 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Arecor Therapeutics plc is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Julie Simmonds | Panmure Liberum |
| Lala Gregorek | Trinity Delta Research Limited |